Background: Cytokines are mediators of disease. Expression levels in the blood could be of clinical relevance. Objective: Aim of this study was to show if serum levels of IL-1β could be of any clinical relevance conc...Background: Cytokines are mediators of disease. Expression levels in the blood could be of clinical relevance. Objective: Aim of this study was to show if serum levels of IL-1β could be of any clinical relevance concerning dogs. IL-1β was measured in serum samples of healthy dogs to find a reference range for healthy individuals. Measurements of IL-1β should show if this substance was a possible marker for early stages of inflammation. Therefore, a possible relation between serum levels and grades of leukocytosis was analyzed. Methods: IL-1β concentrations in the blood were assessed by the use of a human enzyme linked immunosorbent assay (ELISA). 39 dogs with different inflammatory diseases were analyzed to figure out if there was a correlation between IL-1β serum levels and the number of leukocytes in peripheral blood. The control group consisted of 16 healthy dogs. Results: about half of the samples IL-1β were detected. Most of the patients showed no detectable amounts of IL-1β. The IL-1β levels measured in the serum were stable for at least nine weeks when stored at ?20?C. The patients tested positively on IL-1β had mostly lower-grade leukocytosis compared to those who had no IL-1β in serum. All the dogs which were suffering from disease but still had no traceable IL-1β, showed a leukocytosis as a common symptom. Conclusion: This study showed that IL-1β could become an interesting marker for the detection of early stages of inflammation when leukocytosis does not yet appear in peripheral blood. Nonetheless, the possible use in diagnosis is restricted. This is due to the fact that there are only low amounts of IL-1β to be detected in the serum, even concerning patients are suffering from disease.展开更多
【目的】观察解毒活血方干预经皮冠状动脉介入(PCI)术后患者外周血中核因子kappaB(NF-κB)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)的变化及支架内再狭窄(ISR)的发生情况,以期阐明解毒活血方防治ISR的远期疗效及机制。【方...【目的】观察解毒活血方干预经皮冠状动脉介入(PCI)术后患者外周血中核因子kappaB(NF-κB)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)的变化及支架内再狭窄(ISR)的发生情况,以期阐明解毒活血方防治ISR的远期疗效及机制。【方法】选择符合PCI术后纳入标准的患者40例,将PCI术后给予基础治疗者设为对照组,将PCI术后给予基础治疗+解毒活血方治疗者设为中药组,每组各20例。治疗结束后,观察2组临床疗效。于PCI术前及术后24 h、14 d,采用流式细胞仪检测2组患者外周血单个核细胞NF-κB活性,采用酶联免疫吸附法(ELISA)检测2组患者血浆IL-1β及TNF-α表达水平。观察患者术后6个月内心血管事件及ISR的发生情况。【结果】中药组患者的临床疗效显著优于对照组(P<0.05),证候积分及PCI术后6个月内心血管事件和ISR的发生率显著低于对照组(P<0.05或P<0.01)。2组患者PCI术后24 h NF-κB阳性表达率及TNF-α、IL-1β表达水平较治疗前显著升高(P<0.01),但2组差异无统计学意义(P>0.05);2组患者PCI术后14 d NF-κB阳性表达率及TNF-α、IL-1β表达水平较术后24 h显著降低(P<0.01),且中药组降低效果明显优于对照组(P<0.05)。【结论】解毒活血方可降低ISR的发生率,其机制可能与降低NF-κB活性及血浆IL-1β、TNF-α表达水平有关。展开更多
文摘Background: Cytokines are mediators of disease. Expression levels in the blood could be of clinical relevance. Objective: Aim of this study was to show if serum levels of IL-1β could be of any clinical relevance concerning dogs. IL-1β was measured in serum samples of healthy dogs to find a reference range for healthy individuals. Measurements of IL-1β should show if this substance was a possible marker for early stages of inflammation. Therefore, a possible relation between serum levels and grades of leukocytosis was analyzed. Methods: IL-1β concentrations in the blood were assessed by the use of a human enzyme linked immunosorbent assay (ELISA). 39 dogs with different inflammatory diseases were analyzed to figure out if there was a correlation between IL-1β serum levels and the number of leukocytes in peripheral blood. The control group consisted of 16 healthy dogs. Results: about half of the samples IL-1β were detected. Most of the patients showed no detectable amounts of IL-1β. The IL-1β levels measured in the serum were stable for at least nine weeks when stored at ?20?C. The patients tested positively on IL-1β had mostly lower-grade leukocytosis compared to those who had no IL-1β in serum. All the dogs which were suffering from disease but still had no traceable IL-1β, showed a leukocytosis as a common symptom. Conclusion: This study showed that IL-1β could become an interesting marker for the detection of early stages of inflammation when leukocytosis does not yet appear in peripheral blood. Nonetheless, the possible use in diagnosis is restricted. This is due to the fact that there are only low amounts of IL-1β to be detected in the serum, even concerning patients are suffering from disease.
文摘【目的】观察解毒活血方干预经皮冠状动脉介入(PCI)术后患者外周血中核因子kappaB(NF-κB)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)的变化及支架内再狭窄(ISR)的发生情况,以期阐明解毒活血方防治ISR的远期疗效及机制。【方法】选择符合PCI术后纳入标准的患者40例,将PCI术后给予基础治疗者设为对照组,将PCI术后给予基础治疗+解毒活血方治疗者设为中药组,每组各20例。治疗结束后,观察2组临床疗效。于PCI术前及术后24 h、14 d,采用流式细胞仪检测2组患者外周血单个核细胞NF-κB活性,采用酶联免疫吸附法(ELISA)检测2组患者血浆IL-1β及TNF-α表达水平。观察患者术后6个月内心血管事件及ISR的发生情况。【结果】中药组患者的临床疗效显著优于对照组(P<0.05),证候积分及PCI术后6个月内心血管事件和ISR的发生率显著低于对照组(P<0.05或P<0.01)。2组患者PCI术后24 h NF-κB阳性表达率及TNF-α、IL-1β表达水平较治疗前显著升高(P<0.01),但2组差异无统计学意义(P>0.05);2组患者PCI术后14 d NF-κB阳性表达率及TNF-α、IL-1β表达水平较术后24 h显著降低(P<0.01),且中药组降低效果明显优于对照组(P<0.05)。【结论】解毒活血方可降低ISR的发生率,其机制可能与降低NF-κB活性及血浆IL-1β、TNF-α表达水平有关。
